All posts tagged anthony elias

Phase 1 results point to larger trial of enzalutamide and fulvestrant in advanced breast cancer

December 7, 2015 · Comments Off on Phase 1 results point to larger trial of enzalutamide and fulvestrant in advanced breast cancer

Jennifer Richer, PhD, and colleagues report promising results of a phase 1 clinical trial of combination enzalutamide and fulvestrant against advanced breast cancer.

Read the rest of this entry

Cancer Center Expands Resources to Fight Sarcomas
January 8, 2015 · Comments Off on Cancer Center Expands Resources to Fight Sarcomas

The University of Colorado Cancer Center has taken important steps toward joining a small number...

Provider Portrait: Medicine and Music Make a Perfect Match
August 26, 2014 · Comments Off on Provider Portrait: Medicine and Music Make a Perfect Match

The Cancer Center’s Anthony Elias, MD, has kept alive his love for music throughout a distinguished career as a clinician and researcher in breast cancer.

Medical oncology faculty promotions 2014
July 1, 2014 · Comments Off on Medical oncology faculty promotions 2014

Four University of Colorado Cancer Center investigators and Department of Medical Oncology faculty were recently...

Breast Cancer Clinical Trial Results Show Promise
May 1, 2014 · Comments Off on Breast Cancer Clinical Trial Results Show Promise

A clinical trial shows that an experimental drug along with standard chemotherapy is a beneficial...

$5.9M Grant Adds Androgen Receptor as a New Driver and Target in Breast Cancer
October 1, 2013 · Comments Off on $5.9M Grant Adds Androgen Receptor as a New Driver and Target in Breast Cancer

A major Department of Defense grant to researchers Jennifer Richer, PhD, and Anthony Elias, MD, at the University of Colorado Cancer Center aids development of drugs that target androgen receptors as a driver of breast cancer.

Stop Signals
May 31, 2013 · Comments Off on Stop Signals

Researchers at University of Colorado Cancer Center are discovering how androgens drive diseases such as breast and bladder cancers.

AACR News: Studies show increasing evidence that androgen drives breast cancer
April 10, 2013 · Comments Off on AACR News: Studies show increasing evidence that androgen drives breast cancer

Estrogen and progesterone receptors, and the gene HER2 – these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

Clinical trial hits new target in war on breast cancer
December 3, 2012 · Comments Off on Clinical trial hits new target in war on breast cancer

KEY POINTS: In addition to estrogen, progesterone and HER2, androgen drives breast cancer The drug...

Annual retreat shows the CU Cancer Center is greater than the sum of its parts
October 31, 2012 · Comments Off on Annual retreat shows the CU Cancer Center is greater than the sum of its parts

At the annual CU Cancer Center retreat on October 30, Deputy Director Andrew Thorburn, PhD,...

Study finds breast cancer driver, HER2, in 3 percent of lung cancers

July 27, 2017 · No comments

The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2.

Read the rest of this entry